{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:14Z","timestamp":1787028674546,"version":"build-2736575974"},"reference-count":94,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["multiregional active pharmacovigilance project AIFA 2010\/2011 \u201cvalutazione di sicurezza ed appropriatezza prescrittiva ed aderenza alla Terapia di farmaci biologici impiegati in Centri Regionali di Dermatologia, Gastroenterologia e Reumatologia\u201d"],"award-info":[{"award-number":["multiregional active pharmacovigilance project AIFA 2010\/2011 \u201cvalutazione di sicurezza ed appropriatezza prescrittiva ed aderenza alla Terapia di farmaci biologici impiegati in Centri Regionali di Dermatologia, Gastroenterologia e Reumatologia\u201d"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Post-marketing surveillance activities are essential to detect the risk\/benefit profile of biologic disease-modifying antirheumatic drugs (bDMARDs) in inflammatory arthritis. The aim of this study was to evaluate adverse events (AEs) in patients treated with bDMARDs in rheumatology during a prospective pharmacovigilance study from 2016 to 2018. Descriptive statistical analyses were performed to evaluate bDMARDs-related variables of patients without AEs\/failures vs patients with AEs and failures. The risk profile among biologics was assessed by comparing patients treated with each bDMARD to patients treated with etanercept. A total of 1155 patients were enrolled, mostly affected by rheumatoid arthritis (46.0%). AEs and failures were experienced by 8.7% and 23.3%, respectively. The number of comorbidities significantly influenced the onset of AEs, while anxiety-depressive, gastrointestinal disease, and fibromyalgia influenced onset of failures. The probability of developing an AE was significantly lower in patients treated with secukinumab, while the probability of developing treatment failure was significantly lower in patients treated with golimumab, secukinumab and tocilizumab. A total of 216 AEs were reported (25.5% serious), mostly regarding infections (21.8%), musculoskeletal (17.6%) and skin (16.2%) disorders. Serious AEs included neutropenia (12.7%), lymphocytosis (9.1%) and uveitis (7.3%). The obtained results revealed known AEs but real-world data should be endorsed for undetected safety concerns.<\/jats:p>","DOI":"10.3390\/jcm9041227","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T01:29:15Z","timestamp":1588123755000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-4696","authenticated-orcid":false,"given":"Maria Antonietta","family":"Barbieri","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-8679","authenticated-orcid":false,"given":"Giuseppe","family":"Cicala","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Maria","family":"Cutroneo","sequence":"additional","affiliation":[{"name":"Sicilian Regional Pharmacovigilance Centre, University Hospital of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gerratana","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Palleria","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"De Sarro","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Vero","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Manti","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[{"name":"Department of Health Science, School of Medicine, University of Catanzaro, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-7449","authenticated-orcid":false,"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40744-019-0160-8","article-title":"Insight into the quality of life of patients with ankylosing spondylitis: Real-world data from a us-based life impact survey","volume":"6","author":"Rosenbaum","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Katchamart, W., Narongroeknawin, P., Chanapai, W., and Thaweeratthakul, P. (2019). Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0080-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: Estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00296-014-2974-6","article-title":"Prevalence and incidence of rheumatoid arthritis in Italy","volume":"34","author":"Rossini","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03009740600904243","article-title":"Prevalence of spondyloarthropathies in an Italian population sample: A regional community-based study","volume":"36","author":"Salaffi","year":"2007","journal-title":"Scand. J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e000656","DOI":"10.1136\/rmdopen-2018-000656","article-title":"Distinguishing rheumatoid arthritis from psoriatic arthritis","volume":"4","author":"Merola","year":"2018","journal-title":"RMD Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: Etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","article-title":"Managing rheumatic and musculoskeletal diseases-past, present and future","volume":"13","author":"Burmester","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Smolen, J.S., Landew\u00e9, R., Bijlsma, J., Burmester, G., Dougados, M., Kerschbaumer, A., Saag, K., Takeuchi, T., Westhovens, R., and Van Der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","article-title":"Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: A German perspective based on nationwide ambulatory drug prescription data","volume":"38","author":"Steffen","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e021447","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: A retrospective analysis of the RECord-linkage on rheumatic diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40744-016-0034-2","article-title":"The burden of rheumatic diseases: An analysis of an Italian administrative database","volume":"3","author":"Iannazzo","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","article-title":"Factors influencing the choice of first-and second-line biologic therapy for the treatment of rheumatoid arthritis: Real-life data from the Italian LORHEN Registry","volume":"36","author":"Monti","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fphar.2017.00607","article-title":"Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania Region (Italy): BIO-Cam observational study","volume":"8","author":"Scavone","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pupt.2014.01.005","article-title":"Randomized controlled trials and real life studies. Approaches and methodologies: A clinical point of view","volume":"27","author":"Saturni","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","article-title":"Safety profile of biological medicines as compared with non-biologicals: An analysis of the Italian spontaneous reporting system database","volume":"37","author":"Cutroneo","year":"2014","journal-title":"Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3343\/alm.2020.40.2.101","article-title":"Laboratory monitoring of biological therapies in rheumatology: The role of immunogenicity","volume":"40","author":"Benucci","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-019-04874-x","article-title":"Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer","volume":"39","author":"Pundole","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology"},{"key":"ref_24","first-page":"649","article-title":"Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: A survey from the Italian registry GISEA","volume":"37","author":"Atzeni","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/annrheumdis-2015-207870","article-title":"Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis","volume":"75","author":"Zhang","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102401","DOI":"10.1016\/j.autrev.2019.102401","article-title":"Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?","volume":"18","author":"Atzeni","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.berh.2019.02.003","article-title":"Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents","volume":"32","author":"Atzeni","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Marino, F., Nucera, V., Gerratana, E., Fiorenza, A., Sangari, D., Miceli, G., Masala, I.F., and Atzeni, F. (2019). Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis. Pharmacol. Res., 104507.","DOI":"10.1016\/j.phrs.2019.104507"},{"key":"ref_30","unstructured":"(2019, October 07). Ministero del Lavoro, Della Salute e Delle Politiche Sociali Classificazione Delle Malattie, Dei Traumatismi, Degli Interventi Chirurgici Edelle Procedurediagnostiche Eterapeutiche, Available online: http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2251_allegato.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_32","unstructured":"(2019, August 28). European Medicines Agency Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Palleria, C., Iannone, L., Leporini, C., Citraro, R., Manti, A., Caminiti, M., Gigliotti, P., Grembiale, R.D., L\u2019Andolina, M., and Muccari, G. (2018). Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205134"},{"key":"ref_34","first-page":"132","article-title":"MonitorNet: The Italian multi-centre observational study aimed at estimating the risk\/benefit profile of biologic agents in real-world rheumatology practice","volume":"61","author":"Sfriso","year":"2009","journal-title":"Reumatismo"},{"key":"ref_35","first-page":"1","article-title":"Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting","volume":"10","author":"Barros","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","article-title":"Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study","volume":"38","author":"Filippini","year":"2010","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_37","first-page":"205","article-title":"Sex-based differences in autoimmune diseases","volume":"52","author":"Ortona","year":"2016","journal-title":"Ann. Ist. Super. Sanita"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14397595.2016.1193105","article-title":"Gender specific differences in patients with psoriatic arthritis","volume":"27","author":"Nas","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Palazzo, C., Ravaud, J.-F., Papelard, A., Ravaude, P., and Poiraudeau, S. (2014). The Burden of musculoskeletal conditions. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090633"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"vii11","DOI":"10.1093\/rheumatology\/key209","article-title":"The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: Report from a National Consensus Conference","volume":"57","author":"Conti","year":"2018","journal-title":"Rheumatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.reuma.2017.06.002","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: The spanish cohort of the COMORA study","volume":"15","author":"Balsa","year":"2019","journal-title":"Reumatol. Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4081\/reumatismo.2017.898","article-title":"Comorbidities and related factors in rheumatoid arthritis patients of South India-Karnataka rheumatoid arthritis comorbidity (KRAC) study","volume":"69","author":"Chandrashekara","year":"2017","journal-title":"Reumatismo"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5114\/reum.2018.77974","article-title":"Comorbidities in rheumatic arthritis","volume":"56","year":"2018","journal-title":"Reumatologia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/imj.14046","article-title":"Comorbidity in psoriatic arthritis and rheumatoid arthritis","volume":"48","author":"Sinnathurai","year":"2018","journal-title":"Intern. Med. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: A prospective national cohort study","volume":"20","author":"Lee","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/bph.14604","article-title":"Mechanisms of hypertension in autoimmune rheumatic diseases","volume":"176","author":"Taylor","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/rheumatology\/ken443","article-title":"Transforming growth factor-\u03b21 869T\/C, but not interleukin-6 -174G\/C, polymorphism associates with hypertension in rheumatoid arthritis","volume":"48","author":"Panoulas","year":"2009","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.berh.2019.01.021","article-title":"Rheumatoid arthritis and thyroid dysfunction: A cross-sectional study and a review of the literature","volume":"32","author":"Mahagna","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12026-017-8900-8","article-title":"Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: A longitudinal follow-up study","volume":"65","author":"Fallahi","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","article-title":"Concomitant fibromyalgia complicating chronic inflammatory arthritis: A systematic review and meta-analysis","volume":"57","author":"Duffield","year":"2018","journal-title":"Rheumatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/BTT.S168691","article-title":"Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies","volume":"12","author":"Esposti","year":"2018","journal-title":"Biol. Targets Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00508-018-1321-4","article-title":"Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011","volume":"130","author":"Stamm","year":"2018","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/1756-185X.13271","article-title":"Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: A retrospective cohort study in daily practice","volume":"21","author":"Rusman","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_57","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03009742.2014.962081","article-title":"Two-year survival rates of anti-TNF-\u03b1 therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA","volume":"44","author":"Iannone","year":"2015","journal-title":"Scand. J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/TCRM.S194921","article-title":"Drug-related problems in patients with rheumatoid arthritis","volume":"15","author":"Ma","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Iannone, F., Nivuori, M., Fornaro, M., Venerito, V., Cacciapaglia, F., and Lopalco, G. (2019). Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology.","DOI":"10.1093\/rheumatology\/kez505"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: Results of a prospective, multicentre study","volume":"77","author":"Etcheto","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00296-014-2955-9","article-title":"Fibromyalgia in patients with axial spondyloarthritis: Epidemiological profile and effect on measures of disease activity","volume":"34","author":"Salaffi","year":"2014","journal-title":"Rheumatol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","article-title":"Comparative effectiveness of tumour necrosis factor \u03b1 inhibitors in combination with either methotrexate or leflunomide","volume":"68","author":"Strangfeld","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","article-title":"Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","article-title":"Switching between biological treatments in psoriatic arthritis: A review of the evidence","volume":"17","author":"Costa","year":"2017","journal-title":"Drugs R D"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14740338.2020.1681396","article-title":"Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis","volume":"19","author":"Santoleri","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2009.12.010","article-title":"Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry","volume":"9","author":"Caporali","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5114\/reum.2019.87616","article-title":"Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy","volume":"57","author":"Czekalska","year":"2019","journal-title":"Reumatologia\/Rheumatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8030387","article-title":"Golimumab for rheumatoid arthritis","volume":"8","author":"Pelechas","year":"2019","journal-title":"J. Clin. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","article-title":"Long-term safety of abatacept in patients with rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Cassone, G., Manfredi, A., Atzeni, F., Venerito, V., Vacchi, C., Picerno, V., Furini, F., Erre, G.L., Tomietto, P., and Fedele, A.L. (2020). Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010277"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients","volume":"48","author":"Loricera","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_75","first-page":"542","article-title":"Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients","volume":"35","author":"Sebastiani","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e021082","DOI":"10.1136\/bmjopen-2017-021082","article-title":"Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: Non-interventional GO-NICE study in Germany","volume":"8","author":"Burmester","year":"2018","journal-title":"BMJ Open"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/25785826.2019.1605036","article-title":"Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis","volume":"42","author":"Ogawa","year":"2019","journal-title":"Immunol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-\u03b1 antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.6061\/clinics\/2013(09)03","article-title":"The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: A 5-year prospective analysis","volume":"68","author":"Machado","year":"2013","journal-title":"Clinics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/1744666X.2016.1127159","article-title":"Subcutaneous tocilizumab for the treatment of rheumatoid arthritis","volume":"12","author":"Mitchell","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_82","first-page":"470","article-title":"Liver injury in psoriasis patients receiving ustekinumab: A retrospective study of 44 patients treated in the clinical practice setting","volume":"106","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1574886313666180719165212","article-title":"A case of severe transaminase elevation following a single ustekinumab dose with remission after drug withdrawal","volume":"13","author":"Lovero","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Manfredi, A., Cassone, G., Furini, F., Gremese, E., Venerito, V., Atzeni, F., Arrigoni, E., Della Casa, G., Cerri, S., and Govoni, M. (2019). Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicenter retrospective study. Intern. Med. J.","DOI":"10.1111\/imj.14670"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clim.2010.02.004","article-title":"CD4+ T-cells lymphocytosis and reduction of neutrophils during treatment with adalimumab: Challenge and dechallenge study","volume":"135","author":"Ursini","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12026-014-8590-4","article-title":"Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: Case series and review of literature","volume":"61","author":"Shovman","year":"2014","journal-title":"Immunol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.berh.2018.08.002","article-title":"Uveitis and spondyloarthropathies","volume":"31","author":"Sharma","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","article-title":"A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab","volume":"73","author":"Ray","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: Results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: Cohort study based on nationwide prospectively recorded data from Sweden","volume":"28","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: A collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jbspin.2017.08.003","article-title":"Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs","volume":"85","author":"Atzeni","year":"2018","journal-title":"Jt. Bone Spine"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:45:24Z","timestamp":1760363124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/4\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["jcm9041227"],"URL":"https:\/\/doi.org\/10.3390\/jcm9041227","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}